KIMA CBS 29
John Katko (R-NY) said he has seen firsthand at businesses in his district the cost of developing and producing cancer medication, so he does not expect overpricing to be an industry-wide issue. “The question is, are [EpiPens] an outlier or is this …
and more
Read more here:: ATV google
